Health Dictionary Find a Doctor

Autoimmune polyendocrine syndrome natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Overview

If left untreated, patients with autoimmune polyendocrine syndrome (APS) may progress to involve other endocrine and non-endocrine organs. APS can be a life-threatening condition if vital hormone producing organs of the body are involved such as adrenal glands, thyroid, parathyroid glands. The complications of APS depend upon the subtype and organ system involved. Common complications of APS include those arising from hypoparathyroidism, Addison’s disease and autoimmune thyroiditis. The prognosis of APS is variable and depends upon the duration and severity of endocrine/non-endocrine organ involved. Patients of APS with endocrine involvement generally require lifelong hormone replacement therapy.

Natural History, Complications, and Prognosis

Natural History, Complications, and Prognosis

Natural History

Complications

The complications of autoimmune polyendocrine syndrome (APS) depends upon the subtype and endocrine/non-endocrine organ involved.

APS type 1

APS type 2

APS type 3

Prognosis

References

References

  1. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M (2012). “Long-term follow-up of patients with hypoparathyroidism”. J. Clin. Endocrinol. Metab. 97 (12): 4507–14. doi:10.1210/jc.2012-1808. PMC 3513540. PMID 23043192.
  2. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT (2016). “Management of Hypoparathyroidism: Summary Statement and Guidelines”. J. Clin. Endocrinol. Metab. 101 (6): 2273–83. doi:10.1210/jc.2015-3907. PMID 26943719.
  3. Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014). “Postsurgical hypoparathyroidism–risk of fractures, psychiatric diseases, cancer, cataract, and infections”. J. Bone Miner. Res. 29 (11): 2504–10. doi:10.1002/jbmr.2273. PMID 24806578.
  4. Abate EG, Clarke BL (2016). “Review of Hypoparathyroidism”. Front Endocrinol (Lausanne). 7: 172. doi:10.3389/fendo.2016.00172. PMC 5237638. PMID 28138323.
  5. Goswami R, Sharma R, Sreenivas V, Gupta N, Ganapathy A, Das S (2012). “Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism”. Clin. Endocrinol. (Oxf). 77 (2): 200–6. doi:10.1111/j.1365-2265.2012.04353.x. PMID 22288727.
  6. Quinkler M (2012). “[Addison’s disease]”. Med Klin Intensivmed Notfmed (in German). 107 (6): 454–9. doi:10.1007/s00063-012-0112-3. PMID 22907517.
  7. Caturegli P, De Remigis A, Rose NR (2014). “Hashimoto thyroiditis: clinical and diagnostic criteria”. Autoimmun Rev. 13 (4–5): 391–7. doi:10.1016/j.autrev.2014.01.007. PMID 24434360.
  8. Kirshner HS (2014). “Hashimoto’s encephalopathy: a brief review”. Curr Neurol Neurosci Rep. 14 (9): 476. doi:10.1007/s11910-014-0476-2. PMID 25027262.
  9. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, Wang F, Duan Z, Xin S, Zhang J (2013). “Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis”. Otolaryngol Head Neck Surg. 148 (3): 396–402. doi:10.1177/0194599812472426. PMID 23300224.
  10. Ahmed R, Al-Shaikh S, Akhtar M (2012). “Hashimoto thyroiditis: a century later”. Adv Anat Pathol. 19 (3): 181–6. doi:10.1097/PAP.0b013e3182534868. PMID 22498583.
  11. Chiang B, Cheng S, Seow CJ (2016). “Commonly forgotten complication of Hashimoto’s thyroiditis”. BMJ Case Rep. 2016. doi:10.1136/bcr-2016-217568. PMID 27797845.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH